Through a newly-signed expanded agreement with Kaken Pharmaceuticals, Scios Nova's basic fibroblast growth factor is scheduled to enter Phase III clinical testing as a topical treatment for intractable dermal ulcers early this month in Japan.
Fibroblast growth factor is a potent stimulator of angiogenesis and other tissue repair processes, and may be useful in treating soft tissue wounds (dermal ulcers), bone disease (fractures and osteoporosis), periodontal diseases and nerve damage. It may also have a role in the treatment of ischemic heart disease. Kaken has rights to develop the product for all these clinical indications in Japan, Korea, Taiwan, Hong Kong and the People's Republic of China.
The new deal extends a 1988 agreement between the two companies and establishes a bFGF manufacturing collaboration between them. Scios Nova has made the compound available for licensing elsewhere in the world, but has not entered into any other corporate partnerships.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze